PPTA Twitter

PlasmaProteins Individuals may donate #plasma through a process called plasmapheresis. This sterile, self-contained, and automated process separates plasma from other cellular components, which are then returned to the donor. Learn more: bit.ly/2SyNxTt pic.twitter.com/ZkdEYbDl0H

About 10 hours ago.

PlasmaProteins #Plasmaprotein therapies give individuals the ability to lead a normal life. “For patients with CIDP, access to treatment is vital to maintain physical autonomy.” Read Jean-Philippe’s story: bit.ly/2TvhoS2 #PlasmaDonorsSaveLives

1 day ago.

Ethical Considerations in Compensated Plasma Donation

PPTA's standards programs are cited in "Risk-based decision making and ethical considerations in donor compensation for plasma-derived medicinal products," in Transfusion. This Commentary concludes that there is no ethical basis for banning compensated plasma donation. Click here for the full article.

PPTA News

PPTA Letter to American National Red Cross +

Dear Mr. Hrouda:
We read with interest your recently posted, “securing the future of the U.S. blood supply: an open letter to the health care community.” We share your goal of having an accessible, safe and sustainable supply of transfusable blood components. It is in everyone’s interests to ensure that the nation’s blood supply is secure. We also recognize the challenges to the blood community in responding to a changing environment in transfusion therapy to support the patients’ needs.
Read More
PPTA Responds to ARD Documentary +

A recent documentary, “Blood Trade – Health vs. Dollars,” published by a German television network, focuses on the role plasma donors play in providing blood plasma, the starting material used to create therapies for patients around the world living with rare, serious, and sometimes life-threatening diseases. The Plasma Protein Therapeutics Association (PPTA) and its member companies agree with the reporters that plasma donors save lives.
Read More
PPTA Welcomes New Executive Director of European Division +

The Plasma Protein Therapeutics Association (PPTA) announced today that Maarten Van Baelen has joined the association as Executive Director, PPTA Europe. Maarten brings to PPTA more than 10 years in the life sciences arena, including as an advocate for access to generic, biosimilar and value-added medicines. He has represented the pharmaceutical sector’s interest in public forums, strategic policy development, and advocacy on key issues with the European Commission, National Competent Authorities, and other stakeholders.
Read More